What is the potential of p53 isoforms as a predictive biomarker in the treatment of cancer?

Liam Hayman, Wajeeh Raza Chaudhry, Victor V. Revin, Nikolai Zhelev, Jean-Christophe Bourdon (Lead / Corresponding author)

Research output: Contribution to journalReview articlepeer-review

15 Citations (Scopus)
482 Downloads (Pure)


Introduction: For decades, p53 was researched as a single protein with alterations described as mutants. The discovery of 12 human p53 isoforms expressed from 9 transcripts changed this perception, eloquently explaining the numerous roles p53 plays, including apoptosis, senescence, and regeneration. 

Area covered: Here, we summarise the p53 isoforms and their relevance to cancer to establish an understanding and theorise on potential applications of the isoforms in clinical practice. 

Expert commentary: Pertaining to the different expression of isoforms in different tumors, it is concluded that the clinical use of isoforms as prognostic and predictive biomarkers will be different depending on the cell type, the tissue origin of the tumors, the position of the TP53 mutation and the driver-oncogene.

Original languageEnglish
Pages (from-to)149-159
Number of pages11
JournalExpert Review of Molecular Diagnostics
Issue number2
Early online date7 Jan 2019
Publication statusPublished - Feb 2019


  • Apoptosis
  • biomarker
  • cancer
  • p53
  • p53 isoforms
  • tumour

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics


Dive into the research topics of 'What is the potential of p53 isoforms as a predictive biomarker in the treatment of cancer?'. Together they form a unique fingerprint.

Cite this